Canwen Jiang joined RhiaPharmaceutical from Flagship Pioneering where he served as Chief Medical Officer for Laronde Therapeutics, an endless-RNA company, and as Senior Vice President Translational Medicine and Clinical Development at Ring Therapeutics, a gene therapy company. Prior to Flagship, he was co-founder, CEO, and a member of the Board of Directors at Sinovant Sciences. Dr. Jiang also served as Global Therapeutic Area Head, Ophthalmology and ENT at Novartis, and Global Head of Clinical Development and Regional Head of Clinical, Regulatory and Medical Affairs Asia Pacific at its Alcon division over an eight year period. Prior to Novartis, he worked at Sanofi-Genzyme for 17 years with increasing responsibilities in various senior leadership roles including global vice president of R&D and Head of R&D Asia.

Dr. Jiang received his medical degrees and internal medicine training at Hunan College of Medicine and Hunan College of Chinese Medicine. He completed his clinical cardiology fellowship and sub-specialty training at the Royal Brompton and Harefield Hospitals, London, in the UK. Additionally, Dr. Jiang obtained a PhD from Imperial College London and additional scientific and clinical research training at the University of California, Berkeley and San Francisco. Dr. Jiang has co-authored more than 50 peer-reviewed scientific and medical articles and has been granted multiple US and international patents.